Kornimate/medical-research-clean huggingface dataset:
use of high intensity interval training as a strategy to minimize the insulin resistance observed in sleep deprivation

Conditions: Insulin Resistance; Sleep Deprivation

Summary: sleep is an essential biological process for life and great value to functions such as learning, memory processing , cell and brain repair. recently, new evidence points to the relationship between lack of sleep and carbohydrate metabolism , establishing a framework for insulin resistance observed in studies with restriction and sleep deprivation on several nights and in a single night . to reverse this process , one of the most effective strategies is physical exercise and part listed in the literature as a non-pharmacological tool for prevention and health promotion , as well as in the treatment of some diseases . however , the pace of modern society causes people to practice less physical exercise , lack of time being the main reason . in this scenario, the high intensity interval training ( hiit ) emerges as a powerful strategy that induces major changes optimizing the time spent on such activity. considering the benefits of this mode , the purpose of this study is to investigate the effects of high-intensity interval training in the context of insulin resistance observed during sleep deprivation. will be recruited 20 male volunteers, aged between 18 and 35 years old, healthy, with normal sleep duration equivalent to 7-8 hours / night, not smoking and regular eating habits. they will be submitted to a protocol of 6 sessions of high-intensity interval training for two weeks, and since the end period, sleep normally, or be deprived of sleep for 24 hours. biochemical (thyroid hormones, cortisol, glucagon, free fatty acid, cholesterol, glucose and insulin) will be undertaken as well as evaluation of body composition by plethysmography, basal metabolic rate by indirect calorimetry and insulin sensitivity through oral glucose tolerance test (ogtt) before and after the training period.


Eligibility criteria:
inclusion criteria: * healthy * recreationally active * eutrophic * sleep duration about 7-8 hours exclusion criteria: * no smoking * without sleep disorders * nondiabetic
clozapine induced weight gain

Conditions: Weight Gain; Antipsychotic Agents; Pharmacogenetics

Summary: clozapine is prescribed to patients with psychosis in whom other treatments have not worked. research has shown, however, that clozapine may be associated with weight gain and abnormal blood sugar levels in some patients. there is strong evidence to suggest that genetic variation between individuals plays an important role in the development of these side effects in response to the medication. our research aims to evaluate the effects of two genes and the blood level of clozapine on side-effects such as weight changes and blood sugar levels in patients receiving clozapine treatment. from out-patient clinics in cwm taf uhb, the investigators aim to recruit 160 patients who are taking clozapine; collect information/ measurements from recruits relating to size/ weight/ bmi, risk of diabetes and blood samples to measure markers of blood sugar, fat/lipids, clozapine and its breakdown products, blood cells and variants of two specific genes. from this information the investigators will be particularly interested to understand if there is any association between the variation in these two genes with weight gain or changes in blood sugar, in patients taking clozapine.


Eligibility criteria:
inclusion criteria: * age 18 years or over * taking/compliant with clozapine antipsychotic medications. * patients meeting the icd-10 criteria for a diagnosis of schizophrenia, schizoaffective or borderline personality disorders. exclusion criteria: * history of current alcohol/illicit substance dependency. * unable/ unsuitable to complete the study protocol e.g. acutely ill, suicidal or aggressive patients. * unable to consent to the study.
pediatric glittre adl-test in children with asthma

Conditions: Asthma in Children

Summary: the aim of the study is to investigate reliability, validity, of the glittre adl test in children with asthma.

the tglittre-p is an adaptation of the tglittre test for pediatric patients. it consists of completing a circuit while carrying a backpack with a variable weight of 0.5 kg to 2.5 kg, according to the child´s age and sex. this weight range follows the guidelines of the world health organization, which states that the younger the female child is, the lighter the backpack should be, in order to assure the school children´s health condition. the following tasks should be carried out; from a sitting position, the child stands up and walks along a 10m-long flat course, going up and down a 2-step rise (17 cm high x 27 cm wide) about halfway along that distance, to reach a bookshelf with three 0.5 kg objects (i.e. colorful plastic bowling pins filled with sand). the objects are placed on the top shelf at eye level, which should be removed, one by one, to the lower shelf at the level of the umbilicus, and then to the ground. next, the objects should be placed on the lower shelf and then back to the top shelf. the child walks back along the same route. (s)he sits down, stands up and immediately starts the next lap. the following verbal instructions are given during the test: "sit" and "stand." the time required to walk five laps is registered; the less the time spent, the better the performance is. the test performance was evaluated by comparing the patient´s data with the data predicted by the equation, in his study with healthy children. the equation for girls is "time in tglittre-p = 3.781-0.083 x age"; and boys, "time in tglittre-p = 4.025-0.123 x age".

Eligibility criteria:
inclusion criteria: * children and adolescents aged 6-14 years with a diagnosis of asthma * task-oriented and co-operative patients without any musculoskeletal, rheumatic, neurological, hearing and visual diseases and without pulmonary exacerbation at the time of data collection will be included in this study. exclusion criteria: -

Keywords: daily living activities exercise
the effects of chiropractic care in adults with subclinical spinal pain

Conditions: Subclinical Spinal Pain

Summary: this study aims to investigate long term and retention (in a subgroup) effects of chiropractic care (cc) on neurological, behavioral, immunological functions and health-related quality of life in adults with subclinical pain.

there is growing evidence that chiropractic care positively impacts various aspects of central and autonomic nervous system function. a single session of chiropractic adjustment has shown to alter pre-frontal cortex (pfc) activity, but there is a lack of robust research investigating the long-term benefits of such pfc changes. this study aims to investigate long term and retention (in a subgroup) effects of chiropractic care (cc) on neurological, behavioral, immunological functions and health-related quality of life in adults with subclinical pain. in these parallel-group randomized controlled trials, participants aged 18-60 years with subclinical spinal pain will be randomly allocated to receive either 12 weeks of cc intervention or control intervention. primary outcomes include functional near-infrared spectroscopy, heart rate variability (hrv), serum brain-derived neurotrophic factors (bdnf) levels and resting-state electroencephalography (eeg). the secondary outcomes include pfc activity (measured by cognitive and behavioral testing), immune and inflammatory markers and health-related quality of life. as data collected in the project is a combination of extrinsic (sociodemographic, clinical questionnaires etc.) and intrinsic physiological data (physiological measures like eeg, hrv etc.), the machine learning or artificial intelligence (ai) will be used to help the development of optimal chiropractic care plans in future.

Eligibility criteria:
inclusion criteria: * aged between 18 and 60 years * have subclinical spinal pain exclusion criteria: * no evidence of spinal dysfunction is present, they are in current pain (above 3/10 on vas) * have sought previous treatment for their spinal issues * are unable to perform the assessment procedures due to contraindications or movement limitations * diagnosed immune dysfunction * utilizing a prescribed immunosuppressive medication * they have uncontrolled asthma * have nasal polyps * use of an intranasal steroid spray one month or less before the study * are hiv-positive * unable or unwilling to comply with the study protocol * a history of drug abuse * are participating in another research study during the time of data collection. * have any diagnosed comorbidity or concomitant disease * donated blood within last month * have allergies to yeast or yeast-derived products * have chronic sinusitis and/ or recent (within the last six weeks) episodes of acute sinusitis.

Keywords: subclinical spinal pain
pirfenidone for progressive fibrotic sarcoidosis

Conditions: Sarcoidosis, Pulmonary

Summary: study comparing pirfenidone versus placebo for patients with advanced fibrotic sarcoidosis

patients who meet the inclusion and exclusion criteria will be randomized to be treated with either placebo or pirfenidone at the current approved dosage for idiopathic pulmonary fibrosis at a 2:1 pirfenidone to placebo ratio. patients treated with pirfenidone will be titrated using the following schedule: one 267 mg capsules three times a day for two weeks. two 267 mg capsules three times a day for two weeks three 267 mg capsules three times a day thereafter patients will be instructed to take all doses of medication with food. dosage will be titrated on an individual basis depending on patient tolerance of medication. those randomized to placebo will receive the same schedule using placebo tablets. block randomization will be done at each site. liver function tests will be evaluated as listed above. if the patient has an abnormal liver function test, then the dose will be adjusted per the company's protocol for commercial drug.

Eligibility criteria:
inclusion criteria: * diagnosis of sarcoidosis * pulmonary function testing with a composite physiologic index (cpi) score of greater than 40 * patient must have evidence of \>20% fibrosis on high resolution cat scan * patients must be on a stable prednisone therapy for sarcoidosis for at least two months and no change in other immunosuppressives in the two months prior to entry into study * age greater than 18 and less than 90. * able to provide written informed consent for participation in the study exclusion criteria: * patients receiving therapy for precapillary pulmonary hypertension. * patients with liver disease childs class 3 or 4 * patients with a left ventricular ejection fraction of less than 40% * patients receiving more than 20 mg prednisone daily or its equivalent * patients with massive hemoptysis within prior three months. patients with mycetomas are eligible as long as no massive hemoptysis in prior three months. * patients with clinically important co-existing disease which in the opinion of the investigator is likely to affect patient's chance for survival during the course of the study * patient who is pregnant, lactating, intending to become pregnant during the study, or child bearing capacity who is not willing to use appropriate birth control methods approved by investigator

Keywords: pulmonary fibrosis
flavopiridol in treating patients with recurrent prostate cancer

Conditions: Prostate Cancer

Summary: phase ii trial to study the effectiveness of flavopiridol in treating patients with recurrent prostate cancer after hormone therapy. drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

objectives: i. evaluate the clinical effectiveness of flavopiridol in patients with metastatic androgen independent adenocarcinoma of the prostate. ii. assess the toxic effects of flavopiridol in this patient population. outline: patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. after 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation. patients are followed every 3 months until death.

Eligibility criteria:
patient characteristics: * performance status: ecog 0-2 * life expectancy: at least 3 months * wbc at least 3,000/mm3 * absolute neutrophil count at least 1,200/mm3 * platelet count at least 100,000/mm3 * hemoglobin at least 8 g/dl * bilirubin no greater than 1.5 mg/dl * sgot no greater than 2.5 times normal * creatinine no greater than 1.5 mg/dl * prostate-specific antigen at least 10 ng/ml (if bone only disease) * no prior or concurrent maligancies within 5 years, except nonmelanoma skin cancer * no serious medical illness * no cord compression symptoms prior concurrent therapy: * no prior chemotherapy * no prior suramin therapy * prior or concurrent use of luteinizing hormone-releasing hormone allowed (no other concurrent hormonal therapy) * no prior anti-androgen therapy within 4 weeks of study * at least 4 weeks since prior radiotherapy * no prior strontium therapy

Keywords: adenocarcinoma of the prostate stage iv prostate cancer
bryostatin 1 in treating patients with progressive kidney cancer

Conditions: Kidney Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of bryostatin 1 in treating patients who have progressive kidney cancer

objectives: i. determine the response rates in patients with progressive hypernephroma treated with bryostatin 1. ii. determine the toxicity of this regimen in these patients. outline: this is a multicenter study. patients receive bryostatin 1 iv over 24 hours on days 1, 8, and 15. treatment repeats every 4 weeks for 2 courses. for patients with stable or responding disease after completion of course 2, treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 14-25 patients will be accrued for this study within 12-18 months.

Eligibility criteria:
disease characteristics: histologically proven progressive hypernephroma bidimensionally measurable disease with documented progression within 2 months prior to study entry sites of measurable or evaluable disease must be outside prior radiation ports no active symptomatic cns disease patient characteristics: age: 18 and over performance status: who 0-2 life expectancy: greater than 3 months hematopoietic: granulocyte count greater than 1,500/mm3 platelet count greater than 100,000/mm3 hepatic: bilirubin less than 1.17 mg/dl sgot or sgpt less than 2.5 times normal renal: creatinine less than 1.70 mg/dl other: no other prior or concurrent malignancy except adequately treated cone biopsied carcinoma in situ of the cervix or basal cell or squamous cell skin cancer no severe or uncontrolled nonmalignant systemic disease that would make the patient a poor medical risk no uncontrolled active infection not pregnant or nursing fertile patients must use effective contraception during and for 4 weeks after study prior concurrent therapy: biologic therapy: at least 4 weeks since prior immunotherapy and recovered chemotherapy: no prior chemotherapy endocrine therapy: at least 4 weeks since prior endocrine therapy or steroids and recovered no concurrent systemic steroids radiotherapy: see disease characteristics at least 4 weeks since prior radiotherapy and recovered no concurrent radiotherapy surgery: not specified

Keywords: stage i renal cell cancer stage ii renal cell cancer stage iii renal cell cancer stage iv renal cell cancer recurrent renal cell cancer
the safety and efficacy of human umbilical cord mesenchymal stem cells (19#isclife®-aci) in the treatment of acute cerebral infarction

Conditions: Cerebral Infarction

Summary: the purposes of the study is to determine the safety and efficacy of treating acute ischemic stroke patients with human umbilical cord mesenchymal stem cells (huc-msc).

this is a randomized, double-blind, paralleled study. 40 patients will be separated into two groups, and receive basic treatment (aspirin tablet). patients in experimental group will receive huc-msc once a month, total 3 times. after the treatment, investigator will have follow-up visit for 6 months, evaluate the security and efficacy of huc-msc.

Eligibility criteria:
inclusion criteria: * patient within 2 weeks onset of symptoms. * symptoms and signs of clinically definite acute cerebral infarction patients. * ct/mri prove the oxfordshire community stroke project (ocsp) as total anterior circulation infarct (taci), partial anterior circulation infarct (paci), posterior anterior circulation infarct (poci), or obvious neurological deficit lacunar infarction patient. * signed informed consent after understanding all possible benefits and harm. exclusion criteria: * allergic to basic drug * with progressive stroke, transient ischemia attach, cerebral infarction with posterior cerebral hemorrhage, and cerebral arteritis. * tumor, injury, and parasites caused cerebral embolism * rheumatic heart disease, coronary heart disease, and other atrial fibrillation combined heart disease caused cerebral embolism * subject is processing thrombolytic therapy * subject is pregnancy and of childbearing potential or breast feeding * participate in any other clinical trial in last 3 months * bleeding tendency patient; severe bleeding tendency in last 3 month * with gastric duodenal ulcer * participants with severe liver and kidney, hematopoietic, and metabolic diseases; or with liver and kidney function examination abnormal * participants are intolerance with aspirin enteric-coated tablets, or need other antiplatelet drugs * participants: alcoholism, drug addicted, or other situations may complicated the results * under other therapy that possibly influence msc security or efficacy * investigator supposes not suitable to participate this clinical trail

Keywords: acute cerebral infarction umbilical cord mesenchymal stem cells
a non invasive confirmatory sign for correct epidural catheter placement during normal vaginal delivery

Conditions: Normal Delivery Pain

Summary: epidural anesthesia for pain control during normal vaginal delivery is a blind maneuver and so we need a confirmatory sign for being in the correct epidural space. loss of resistance sign using air may guide us wrongly as it may occur if we entered into the paravertebral muscles or cavities in the interspinal ligaments. so, additional confirmatory sign beside loss of resistance sign by air is strongly needed. we noticed that after occurence of loss of resistance sign by air and insertion of the epidural catheter a dew was formed on the internal sides of the epidural catheter after aspiration to be sure that there are no blood or cerebrospinal fluid in the catheter. this dew formation (ramy sign) is characteristic for air in the epidural space when transferred from the warm epidural space (temperature about 38-39 celsius degree) to the colder aspect of the catheter outside the patient which nearly has the same operating room temperature (22 celsius degree). this sign may be associated with correct placement and good function of the epidural catheter.

parturient for normal vaginal delivery are examined for correct epidural catheter placement by loss of resistance technique by air, observation of the dew sign and epidurogram. visual analogue score is used to test pain. blood pressure and heart rate after epidural injection will be monitored

Eligibility criteria:
inclusion criteria: * parturient for normal vaginal delivery * american society of anesthesiologists 2 exclusion criteria: * patients refusal * back infection * anticoagulant non stopped * platelets count less than 100000 * international normalization ratio more than 1.4 * severe cardiac or respiratory diseases * haemodynamics unstable patients
the expression of pten protein and mrna in malignant cells of chronic myelomonocytic leukemia

Conditions: Chronic Myelomonocytic Leukemia

Summary: the purpose of this study is to evaluate the level of a specific protein (pten) in the cancer cells of chronic myelomonocytic leukemia (cmml) patients. this protein might be involved in the transformation from normal blood cells to leukemia cells. the pten protein has not been investigated in cmml specifically but it has been discovered in closely related cancers. if this study demonstrates an abnormality in this protein, future testing will be designed to evaluate the genetic abnormality that resulted in lack of the normal presence of this protein. the goal is that the results of this study will help to develop new drugs and strategies to treat the future patients with cmml by understanding the abnormality of the disease at the cellular and molecular levels. the results of this study can also be utilized by future studies to develop individualized treatment to patients who have abnormal levels of this protein.


Eligibility criteria:
inclusion criteria: * subject must be at least 18 years or older. * subject must sign informed consent. * for study population only, the subject must have a cmml diagnosis based on the who 2009 criteria. * for control population only, the subject must be deemed healthy with no hematologic disorders.

Keywords: to evaluate the phosphate and tension homolog deleted on chromosome ten (pten) protein level in leukemia cells from patients with cmml. to identify the pten genetic defect in patients with deficient pten protein levels. to evaluate the role of pten deregulation in cmml pathogenesis.
a phase i multicenter clinical trial to evaluate the safety and immunogenicity of vaccinia derived hiv-1 recombinant envelope glycoprotein (gp160) of human immunodeficiency virus: evaluation of a 200-mcg dose

Conditions: HIV Infections

Summary: to determine the safety of and immune response to vaccinia-derived hiv-1 recombinant envelope glycoprotein (gp160) at a dose of 200 mcg in human volunteers; to evaluate duration of antibody response and its relationship to the dose and frequency of inoculation. although recent advances have been made in antiviral therapy against aids, there is currently no cure for aids. it is likely that the ultimate control of the disease depends on the development of safe and effective vaccines against hiv.

although recent advances have been made in antiviral therapy against aids, there is currently no cure for aids. it is likely that the ultimate control of the disease depends on the development of safe and effective vaccines against hiv. healthy, adult volunteers without identifiable high-risk behavior for hiv-1 infection are randomly assigned to receive three injections of either 200 mcg gp160 vaccine or a placebo. at each participating site, four volunteers receive vaccine and two volunteers receive placebo. primary immunization and two booster immunizations at day 30 and day 180 are done in an outpatient setting. volunteers are closely monitored for the first 2 weeks postimmunization (primary and boosters), and extensively followed for 2 years. volunteers may be offered an additional booster of the same preparation at 12 months.

Eligibility criteria:
inclusion criteria patients must be: * normal, healthy, hiv-negative adults who fully comprehend the purpose and details of the study. * available for 2 years of follow-up. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * history of positive ppd (tuberculin test) and abnormal chest x-ray. * positive syphilis serology (e.g., rpr). * positive for circulating hepatitis b surface antigen. patients with the following are excluded: * they or their sexual partners have identifiable high-risk behavior for hiv infection. * history of immunodeficiency or chronic illness. * evidence of psychological or psychiatric problems that may lead to noncompliance. prior medication: excluded: * immunosuppressive medications. prior treatment: excluded: * blood transfusions or cryoprecipitates within the past 6 months.

Keywords: vaccines, synthetic vaccinia virus viral vaccines hiv-1 hiv envelope protein gp160 aids vaccines hiv seronegativity hiv preventive vaccine